In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galmed Pharmaceuticals Ltd.

www.galmedpharma.com

Latest From Galmed Pharmaceuticals Ltd.

Will A US FDA Advisory Committee Be In Intercept's Future?

There are strong reasons to justify an advisory committee meeting for the NASH application, but also an outlet for the US FDA to skip it.

Advisory Committees Drug Review

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Intercept hopes to be first to market in NASH with an indication to treat fibrosis. It also is enrolling a study to show a benefit in NASH patients with cirrhosis.

Drug Approval Standards Clinical Trials

Intercept Could Face Tougher Road To NASH Approval In EU Than US

Recently filed NDA for obeticholic acid relies on US FDA's specified endpoints for treatment of fibrosis, but European standards are less clear cut, the company acknowledges.

Drug Approval Standards Clinical Trials

Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs

Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Galmed International Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Galmed Pharmaceuticals Ltd.
  • Senior Management
  • Allen Baharaff, Pres. & CEO
    Yohai Stenzler, CFO
    Liat Hayardeny, PhD, CSO
    Tali Gorfine, MD, CMO
    Guy Nehemya, VP, Operations
  • Contact Info
  • Galmed Pharmaceuticals Ltd.
    Phone: (972) 3 693 8448
    16 Tiomkin St.
    Tel Aviv, 6578317
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register